Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 28, 2008
Protalix BioTherapeutics, Inc.
(Exact name of registrant as specified in its charter)
| Florida | 000-27836 | 65-0643773 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
2 Snunit Street
Science Park
POB 455
Carmiel, Israel 20100
Science Park
POB 455
Carmiel, Israel 20100
(Address of principal executive offices) (Zip Code)
(Former Name or Former Address, if Changed Since Last Report)
Registrant’s telephone number, including area code: +972-4-988-9488
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
| Item 7.01. Regulation FD Disclosure | ||||||||
| Item 9.01. Financial Statements and Exhibits | ||||||||
| SIGNATURES | ||||||||
| EX-99.1: PRESS RELEASE | ||||||||
Table of Contents
| Item 7.01. | Regulation FD Disclosure |
On October 28, 2008, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release
announcing that Dr. David Aviezer, the Company’s President and Chief Executive Officer, will
present at the 19th Annual Oppenheimer Healthcare Conference on Monday, November 3, 2008, at 4:00
PM EDT. The Company also announced that Dr. Aviezer will present at the Barclays Capital Small &
Mid-Cap Healthcare Conference on Thursday, November 6, 2008, at 9:30 AM EDT. A copy of the press
release is furnished as Exhibit 99.1 to this Report.
Audio webcasts of the presentations will be available on the Company’s website at www.protalix.com
under the events calendar section.
| Item 9.01. | Financial Statements and Exhibits |
| (d) | Exhibits |
| 99.1 | Press release dated October 28, 2008. |
2
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PROTALIX BIOTHERAPEUTICS, INC. | ||||
Date: October 28, 2008
|
By: | /s/ David Aviezer | ||
| Name: | David Aviezer, Ph.D. | |||
| Title: | President and Chief Executive Officer | |||
3
Exhibit 99.1
Protalix BioTherapeutics to Present at to Present at Oppenheimer Annual Healthcare Conference and
at Barclays Capital Small & Mid-Cap Health Care Conference
CARMIEL, Israel, October 28, 2008 (Business Wire) — Protalix BioTherapeutics, Inc. (Amex: PLX),
announced today that Dr. David Aviezer, President and Chief Executive Officer, will present at the
19th Annual Oppenheimer Healthcare Conference on Monday, November 3, 2008, at 4:00 PM EDT. The
conference is being held at the Waldorf Astoria Hotel in New York City.
Dr. David Aviezer will also be presenting at the Barclays Capital Small & Mid-Cap Healthcare
Conference on Thursday, November 6, 2008, at 9:30 AM EDT. The conference is being held at the US
headquarters of Barclays Capital in New York City.
Audio webcasts of the corporate presentations will be available on the Company’s website at
www.protalix.com under the events calendar section.
About Protalix BioTherapeutics
Protalix is a biopharmaceutical company. Its goal is to become a fully integrated
biopharmaceutical company focused on the development and commercialization of proprietary
recombinant therapeutic proteins to be expressed through its proprietary plant cell based
expression system. Protalix’s ProCellEx™ presents a proprietary method for the expression of
recombinant proteins that Protalix believes is safe and scalable and will allow for the
cost-effective, industrial-scale production of recombinant therapeutic proteins. Protalix is
enrolling and treating patients in its pivotal phase III clinical trial in Israel, Europe the
United States and other locations for its lead product candidate, prGCD, for its enzyme replacement
therapy for Gaucher disease, a lysosomal storage disorder in humans, and has reached an agreement
with the United States Food and Drug Administration on the final design of the pivotal phase III
clinical trial through the FDA’s Special Protocol Assessment (SPA) process. Protalix is also
advancing additional recombinant biopharmaceutical drug development programs.
Contact:
The Trout Group, LLC
Marcy Strickler, 646-378-2927
mstrickler@troutgroup.com
Marcy Strickler, 646-378-2927
mstrickler@troutgroup.com